Impact of RSV hospitalization on healthcare costs, caregivers’ productivity loss, and quality of life in children ≤ 2 years old in five European countries
Open Access
- 25 October 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (11) , 1-12
Abstract
Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in young children globally. We evaluated direct medical costs, caregiver work loss, and child quality of life (QoL) impairment associated with RSV hospitalization. Children ≤ 2 years with laboratory-confirmed RSV infection were prospectively identified between October 2020 and May 2023 at ten hospitals in Germany, Spain, Italy, France, and England. Direct costs were calculated based on country-specific unit costs per hospital day. Productivity loss and QoL impairment were ascertained by two validated, caregiver-administered instruments: 1) Work Productivity and Activity Impairment Questionnaire: Child’s Hospitalization for Respiratory Illness (WPAI:CHRI), administered before discharge and 2) TNO AZL Child Quality of Life (TAPQOL), administered at baseline (shortly after admission) and before discharge. Among 382 hospitalized children, 261 (69%) were < 6 months and 306 (80%) were previously healthy. Median length of stay was 6 days (Interquartile Range (IQR) 4–8) and 50 (13%) were admitted to Paediatric Intensive Care Unit (PICU). Median hospital costs/admission were €4,266 (IQR 2,438–8,442), substantially varying by country (range €2,377-€8,541). Productivity loss was substantial with 129/211 (61%) employed caregivers reporting lost work-hours (mean 30.5 ± 18/admission). Child QoL was significantly reduced during RSV hospitalization in most domains, with the highest QoL impairment observed in the lung domain (mean difference 34.2 out of 100 [95% CI 30–38.4]. Conclusion: RSV hospitalization in children ≤ 2 years was associated with significant costs and QoL impairment in five European countries, emphasizing the importance of preventing severe RSV disease. What is known: • RSV is a major cause of hospitalization in young children under 5 years of age globally. • Most hospitalized children with RSV are previously healthy. What is new: • RSV hospitalization in children ≤2 years was associated with significant costs in Europe, with median hospital costs per admission at €4,266, substantial varying by country (range: €2,377 - €8,541). • Caregivers of children ≤ 2 years hospitalized with RSV reported substantial productivity loss and a reduction in the quality of life of their child during hospitalization, as measured using validated instruments (WPAI-CHRI and TAPQOL).Keywords
Funding Information
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
This publication has 32 references indexed in Scilit:
- Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020–2023 in EuropeEuropean Journal of Pediatrics, 2025
- Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 PandemicJAMA Network Open, 2023
- Comparative analysis of RSV-related hospitalisations in children and adults over a 7 year-period before, during and after the COVID-19 pandemicJournal of Clinical Virology, 2023
- Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in EuropeVaccine, 2023
- The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort studyThe Lancet Respiratory Medicine, 2022
- Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeThe Lancet Infectious Diseases, 2022
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Clinical course and cost assessment of infants with a first episode of acute bronchiolitis presenting to the emergency department: Data from the GUERANDE clinical trialPediatric Pulmonology, 2021
- Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, FranceVaccine, 2018
- Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in GermanyEuropean Journal of Pediatrics, 2005